DrugPatentWatch Database Preview
Email this page to a colleague» See Plans and Pricing
« Back to Dashboard
The generic ingredient in EGATEN is triclabendazole. There is one drug master file entry for this compound. One supplier is listed for this compound. Additional details are available on the triclabendazole profile page.
Generic Entry Opportunity Date for 208711
Generic Entry Date for 208711*:
Constraining patent/regulatory exclusivity:
INDICATED FOR THE TREATMENT OF FASCIOLIASIS IN PATIENTS 6 YEARS OF AGE AND OLDER
*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.
Profile for product number 001
|Approval Date:||Feb 13, 2019||TE:||RLD:||Yes|
|Regulatory Exclusivity Expiration:||Feb 13, 2026|
|Regulatory Exclusivity Use:||INDICATED FOR THE TREATMENT OF FASCIOLIASIS IN PATIENTS 6 YEARS OF AGE AND OLDER|
|Regulatory Exclusivity Expiration:||Feb 13, 2024|
|Regulatory Exclusivity Use:||NEW CHEMICAL ENTITY|
Complete Access Available with Subscription